Hikma Pharmaceuticals PLC provided revenue guidance for 2022. Injectables revenue growth in the low to mid-single digits, with core operating margin in the range of 35% to 37%. Generics revenue growth in the range of 8% to 10% and core operating margin in the range of 24% to 25%.

Branded revenue expected to be in line with 2021. Excluding the impact of hyperinflation in 2021, expect Branded revenue to grow in the mid-single digits.